Drug intelligence / Profile preview

raddeanin a

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Raddeanin A is a **natural triterpenoid saponin** isolated from the roots of *Anemone raddeana*, a traditional Chinese medicinal herb. Raddeanin A exhibits potent **anticancer and antiangiogenic activities**, impeding proliferation, inducing apoptosis, and suppressing invasion in numerous human tumor cells, including hepatocellular carcinoma, gastric cancer, non-small cell lung carcinoma, prostate cancer, cholangiocarcinoma, and breast cancer. Its **mechanisms of action** include enhancement of natural killer (NK) cell cytotoxicity via modulation of the MAPK (ERK, p38, JNK) and Ras/Raf/MEK signaling pathways, induction of apoptosis through both caspase-dependent and caspase-independent mechanisms, and **inhibition of angiogenesis** through blockade of VEGFR2 and downstream kinases (PLCγ1, JAK2, FAK, Src, Akt). Raddeanin A also inhibits osteoclastogenesis, reducing tumor-associated bone osteolysis, and can downregulate androgen receptor signaling in prostate cancer cells[1][2][3][5].

Other names
Anemodeanin AOleanolic acid 3-O-alpha-rhamnopyranosyl(1-2)-beta-glucopyranosyl(1-2)-alpha-arabinopyranoside89412-79-3
02

Targets

Ras/Raf/MEK/ERK signaling pathway (MAPK pathway)

Beyond the preview

Go deeper on raddeanin a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on raddeanin a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call